Skip to content
Our Office +972-8-9301-015 |office@biokine.com
Biokine Therapeutics Logo
  • Home
  • About Biokine
    • Company Profile
    • Managment Team
    • Board of Directors
  • Pipeline
    • clinical
    • Pre-clinical
  • News & Events
  • Partnering
    • Investors
  • Contact
  • Home
  • About Biokine
    • Company Profile
    • Managment Team
    • Board of Directors
  • Pipeline
    • clinical
    • Pre-clinical
  • News & Events
  • Partnering
    • Investors
  • Contact

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

Home/BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016
Previous Next

BioLineRx Discloses Positive Correlative Data from Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH 2016

אמיר כספי2021-04-25T08:04:54+00:00November 3rd, 2016|Uncategorized|

Recent Posts

  • Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
  • BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
  • BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
  • BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
  • Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.

Recent Comments

    Archives

    • May 2021
    • December 2020
    • October 2020
    • May 2020
    • February 2020
    • January 2020
    • December 2019
    • November 2019
    • March 2019
    • October 2018
    • August 2018
    • July 2018
    • May 2018
    • January 2018
    • December 2017
    • July 2017
    • June 2017
    • March 2017
    • January 2017
    • November 2016
    • September 2016
    • March 2016
    • January 2016
    • November 2015
    • August 2015
    • June 2015
    • May 2015
    • March 2015
    • January 2015
    • December 2014
    • November 2014
    • September 2014
    • August 2014
    • July 2014
    • June 2014
    • April 2014
    • March 2014
    • February 2014
    • January 2014
    • December 2013
    • November 2013
    • September 2013
    • August 2013
    • June 2013
    • November 2012
    • September 2012

    Categories

    • No categories

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • Popular
    • Recent
    • Comments
    • BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
      September 4th, 2012
    • BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting
      November 7th, 2012
    • BioLineRx Enrolls First Patient in Phase 2 Clinical Trial
      June 6th, 2013
    • Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
      December 16th, 2020
    • BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
      October 30th, 2020
    • BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
      May 27th, 2020
    • BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
      February 27th, 2020
    • Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.
      January 14th, 2020
    • Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE
      December 13th, 2019
    • BioLineRx Presents Preclinical Data From Triple Combination of BL-8040
      November 5th, 2019
    • BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
      March 27th, 2019
    • BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
      October 3rd, 2018
    • BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
      August 7th, 2018
    • BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
      July 30th, 2018
    • BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
      May 17th, 2018
    • BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
      May 16th, 2018
    • BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
      January 23rd, 2018
    • BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
      December 21st, 2017
    • BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML
      December 4th, 2017
    • BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration
      July 10th, 2017
    • BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors
      June 1st, 2017
    • BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
      March 20th, 2017
    • BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
      March 3rd, 2017
    • No comments have been published yet.

    Our Company Mission

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    The Avada Philosophy

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    The Avada Promise

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    We Can Deliver On Projects

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    Recent Works

    Recent Posts

    • Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
    • BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
    • BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
    • BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
    • Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.
    Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consec tetur, adipisci velit, sed quia non numquam eius modi tempora voluptas amets unser.
    John Doe, My Company
    Aliquam erat volutpat. Quisque at est id ligula facilisis laoreet eget pulvinar nibh. Suspendisse at ultrices dui. Curabitur ac felis arcu sadips ipsums fugiats nemis.
    Luke Beck, Theme Fusion

    Contact Info

    12345 north Street
    New York City, NY 555555

    Phone: 555-555-5555

    Fax: 555-555-5555

    Email: info@yourwebsite.com

    Web: Yourwebsite.com

    • Popular
    • Recent
    • Comments
    • BioLineRx In-Licenses a Novel, Phase II Ready Drug for the Treatment of Leukemia and Other Hematological Cancers
      September 4th, 2012
    • BioLineRx Announces BKT-140/BL-8040, for the Treatment of Leukemia and Other Types of Hematological Cancer, to be Presented at 2012 ASH Annual Meeting
      November 7th, 2012
    • BioLineRx Enrolls First Patient in Phase 2 Clinical Trial
      June 6th, 2013
    • Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
      December 16th, 2020
    • BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
      October 30th, 2020
    • BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
      May 27th, 2020
    • BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
      February 27th, 2020
    • Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.
      January 14th, 2020
    • Updated Phase 2a Data From Triple Combination Arm of COMBAT/KEYNOTE
      December 13th, 2019
    • BioLineRx Presents Preclinical Data From Triple Combination of BL-8040
      November 5th, 2019
    • BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
      March 27th, 2019
    • BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
      October 3rd, 2018
    • BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
      August 7th, 2018
    • BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
      July 30th, 2018
    • BioLineRx Reports Results of Phase 2 Study for BL-8040 Monotherapy in Stem Cell Mobilization for Allogeneic Bone Marrow Transplantation
      May 17th, 2018
    • BioLineRx Announces Grant of European Patent Covering Use of BL-8040 with Cytarabine for Treating Acute Myeloid Leukemia
      May 16th, 2018
    • BioLineRx Presents Preclinical Data at ASCO-SITC Showing BL-8040 Prolongs Survival by Mediating Tumor Infiltration of Antigen-Specific T-cells
      January 23rd, 2018
    • BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
      December 21st, 2017
    • BioLineRx Reports Overall Survival Results from Long-Term Follow-Up of Phase 2a Trial in r/r AML
      December 4th, 2017
    • BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer under Immunotherapy Collaboration
      July 10th, 2017
    • BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination with Atezolizumab for Solid Tumors
      June 1st, 2017
    • BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment
      March 20th, 2017
    • BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA
      March 3rd, 2017
    • No comments have been published yet.

    Our Company Mission

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    The Avada Philosophy

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    The Avada Promise

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    We Can Deliver On Projects

    Fugiat dapibus, tellus ac cursus commodo, mauris sit condim eser ntumsi nibh, uum a justo vitaes amet risus amets un. Posi sectetut amet fermntum orem ipsum quia dolor sit amet, consectetur, adipisci velit, sed quia nons.

    Recent Works

    Recent Posts

    • Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)
    • BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization.
    • BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine.
    • BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
    • Bio BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe.
    Neque porro quisquam est, qui dolorem ipsum quia dolor sit amet, consec tetur, adipisci velit, sed quia non numquam eius modi tempora voluptas amets unser.
    John Doe, My Company
    Aliquam erat volutpat. Quisque at est id ligula facilisis laoreet eget pulvinar nibh. Suspendisse at ultrices dui. Curabitur ac felis arcu sadips ipsums fugiats nemis.
    Luke Beck, Theme Fusion

    Contact Info

    12345 north Street
    New York City, NY 555555

    Phone: 555-555-5555

    Fax: 555-555-5555

    Email: info@yourwebsite.com

    Web: Yourwebsite.com

    Copyright © 2020 Biokine LTD | All Rights Reserved |
    Site By: Psik Advertising
    Go to Top